These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6191877)

  • 1. New anthracenedione derivatives: interaction with DNA and biological effects.
    Palumbo M; Antonello C; Viano I; Santiano M; Gia O; Gastaldi S; Magno SM
    Chem Biol Interact; 1983 Jun; 44(3):207-18. PubMed ID: 6191877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bis-substituted hydroxy-anthracenediones: DNA binding and biological activity.
    Palumbo M; Palù G; Gia O; Ferrazzi E; Gastaldi S; Antonello C; Meloni GA
    Anticancer Drug Des; 1987 Apr; 1(4):337-46. PubMed ID: 3450303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A search for potential antitumor agents: biological effects and DNA binding of a series of anthraquinone derivatives.
    Palù G; Palumbo M; Antonello C; Meloni GA; Marciani-Magno S
    Mol Pharmacol; 1986 Feb; 29(2):211-7. PubMed ID: 3951432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity.
    Gatto B; Zagotto G; Sissi C; Cera C; Uriarte E; Palù G; Capranico G; Palumbo M
    J Med Chem; 1996 Aug; 39(16):3114-22. PubMed ID: 8759632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of bis-substituted 2-aza-anthracenedione regioisomers to DNA: effects of the relative positioning of the side chains.
    Sissi C; Moro S; Zagotto G; Ellis M; Krapcho AP; Menta E; Palumbo M
    Anticancer Drug Des; 1999 Jun; 14(3):265-74. PubMed ID: 10500501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between second generation anthracyclines and DNA in the nucleosomal structure.
    Cera C; Palù G; Magno SM; Palumbo M
    Nucleic Acids Res; 1991 May; 19(9):2309-14. PubMed ID: 2041771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bis(alkylamino)anthracenedione antineoplastic agent metabolic activation by NADPH-cytochrome P-450 reductase and NADH dehydrogenase: diminished activity relative to anthracyclines.
    Kharasch ED; Novak RF
    Arch Biochem Biophys; 1983 Jul; 224(2):682-94. PubMed ID: 6408991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aza-bioisosteres of 9, 10-anthracenedione: a modulation of DNA sequence specificity.
    Sissi C; Capranico G; Menta E; Palumbo M
    Mol Pharmacol; 1996 Oct; 50(4):838-45. PubMed ID: 8863828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones.
    de Isabella P; Palumbo M; Sissi C; Carenini N; Capranico G; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC; Zunino F
    Biochem Pharmacol; 1997 Jan; 53(2):161-9. PubMed ID: 9037248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of new anthraquinone derivatives.
    Ferrazzi E; Palumbo M; Valisena S; Antonello C; Palù G
    Chemioterapia; 1986 Oct; 5(5):330-6. PubMed ID: 3791481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular uptake and inhibition of DNA synthesis by dihydroxyanthraquinone and two analogues.
    Nishio A; Uyeki EM
    Cancer Res; 1983 May; 43(5):1951-6. PubMed ID: 6339045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, DNA-binding and cytotoxic properties of a bis(netropsin)-anthracenedione conjugate.
    Boitte N; Pommery N; Colson P; Houssier C; Waring MJ; Hénichart JP; Bailly C
    Anticancer Drug Des; 1997 Sep; 12(6):481-501. PubMed ID: 9311557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental antitumor activity of aminoanthraquinones.
    Johnson RK; Zee-Cheng RK; Lee WW; Acton EM; Henry DW; Cheng CC
    Cancer Treat Rep; 1979 Mar; 63(3):425-39. PubMed ID: 427824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA complexing antibiotics: daunomycin, adriamycin and their derivatives.
    Marco A; Arcamone F
    Arzneimittelforschung; 1975 Mar; 25(3):368-74. PubMed ID: 1174034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of anthracenediones and their photoaffinity analogs.
    Chou KM; Krapcho AP; Horn D; Hacker M
    Biochem Pharmacol; 2002 Mar; 63(6):1143-7. PubMed ID: 11931847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between cytotoxicity and DNA damage in mammalian cells treated with anthracenedione derivatives.
    Locher SE; Meyn RE
    Chem Biol Interact; 1983 Sep; 46(3):369-79. PubMed ID: 6357512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationship study of anthraquinones: 1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethoxy)ethyl]amino]-9,10-anthracenedione, an analog of an established antineoplastic agent.
    Zee-Cheng RK; Cheng CC
    J Pharm Sci; 1982 Jun; 71(6):708-9. PubMed ID: 7097541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and in vitro cytotoxicity of 1-azaanthraquinone-3-carboxamides.
    Lee H; Lee CW; Yang SI
    Arch Pharm Res; 1999 Aug; 22(4):380-3. PubMed ID: 10489877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adriamycin analogues. Preparation and antitumor evaluation of 7-O-(beta-D-glucosaminyl)daunomycinone and 7-O-(beta-D-glucosaminyl)adriamycinone and their N-trifluoroacetyl derivatives.
    Israel M; Murray RJ
    J Med Chem; 1982 Jan; 25(1):24-8. PubMed ID: 7086817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.
    Mansour OC; Evison BJ; Sleebs BE; Watson KG; Nudelman A; Rephaeli A; Buck DP; Collins JG; Bilardi RA; Phillips DR; Cutts SM
    J Med Chem; 2010 Oct; 53(19):6851-66. PubMed ID: 20860366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.